TNFRSF17 and plasma cell myeloma: Two B-cell maturation antigen (BCMA) directed CAR-T products, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are approved for patients with R/R multiple myeloma (RRMM).